2C-P-NBOMe Stats & Data

• Extreme potency: NBOMes are active at sub‑milligram doses; dosing errors of tens of micrograms can cause severe toxicity. Avoid eyeballing; use a 0.001 g (1 mg) scale and volumetric dosing. Erowid and TripSit emphasize microgram‑level potency and dosing caution for the NBOMe series.

• Preferred ROA is buccal/sublingual; swallowed (oral) doses are often poorly active due to first‑pass metabolism, while insufflation/vaporization produce faster, harsher onsets and appear over‑represented in adverse events. Community sources consistently report poor oral activity and recommend buccal administration.

• Medical risks: NBOMes have been linked to severe vasoconstriction, hypertension, agitation, seizures, and deaths at what users considered “normal” recreational doses; EU‑level risk assessment documented confirmed toxicities with 25I‑NBOMe and highlighted risks for the class. Seek urgent care for severe chest pain, bluish/cold extremities, or seizures.

• Avoid combinations: TripSit categorizes NBOMes with stimulants (amphetamines/cocaine/MDMA) as unsafe due to additive cardiovascular strain and higher seizure risk; tramadol is unsafe (seizure threshold); MAOIs are caution due to potentiation and unpredictability; cannabis can unpredictably potentiate psychedelics.

• Mis‑sold risk: NBOMes have frequently been sold as LSD or 2C‑B; use multiple reagents and do not rely on taste. If Ehrlich (indole) test is negative on blotter, LSD is unlikely; NBOMe often shows no Ehrlich reaction. Extract blotter into alcohol before testing to avoid paper/ink artefacts.

• Reagent pointers: NBOMes can show yellow→green reactions with Marquis/Mecke/Mandelin depending on the specific 25X; they are typically Ehrlich negative (unlike LSD). Use a panel (e.g., Marquis, Mecke/Mandelin, Ehrlich) and interpret carefully.

• Plan for a long experience and avoid redosing: plateaus can be protracted with lingering stimulation after visuals fade; redosing has precipitated anxiety and medical events in reports.

• Form matters: substances may be sold as freebase or HCl, and some products are pre‑complexed (e.g., HPBCD) to increase mucosal absorption; bioavailability and potency can differ by preparation—dose conservatively.

• Environment: due to stimulation and vasoconstriction, avoid overheating, heavy exertion, and additional vasoconstrictors (nicotine, high caffeine); maintain hydration with electrolytes but avoid overhydration. This is inferred harm‑reduction from reported adverse signs and TripSit stimulant‑combination cautions.

• Emergency calming: benzodiazepines can reduce agitation and seizure risk but will largely abort the experience; combining recreationally is discouraged due to respiratory/CNS depression risks if other depressants are present. Use only with medical oversight or clear need. (Generalized from TripSit interaction notes and NBOMe case narratives.)